Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4)

Link copied
Case Copied 70 min read

FEDERAL COURT OF AUSTRALIA

Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) [2015] FCA 634

Citation: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) [2015] FCA 634
Parties:

OTSUKA PHARMACEUTICAL CO., LTD and BRISTOL-MYERS SQUIBB COMPANY v GENERIC HEALTH PTY LTD;

GENERIC HEALTH PTY LTD v OTSUKA PHARMACEUTICAL CO., LTD and BRISTOL-MYERS SQUIBB COMPANY 
File number(s): NSD 121 of 2012
Judge(s): YATES J
Date of judgment: 29 June 2015
Catchwords:

PATENTS – standard patent for the use of a carbostyril compound for the production of a medicament having certain features and a method for treating a patient involving the use of the carbostyril compound – where the carbostyril compound (aripiprazole) is claimed to be effective in treating disorders of the central nervous system associated with the 5‑HT1A receptor subtype – treatment of cognitive impairment in schizophrenia

PATENTS – Swiss type claims – discussion of derivation of this form of claim – whether Swiss type claim should be characterised as a method or process

PATENTS – the person skilled in the art considered as a team – whether the team can be differently constituted depending on the patent question involved

PATENTS – infringement – Swiss type claim – whether claim can be infringed by exploitation in the patent area of a medicament manufactured outside the patent area – discussion of Saccharin doctrine

PATENTS – infringement – application of s 117(2)(b) of the Patents Act 1900 (Cth) to a method of treating the human body with a pharmaceutical product

PATENTS – validity – novelty

PATENTS – validity – manner of new manufacture – whether an invention is disclosed on the face of the specification

PATENTS – validity – inventive step – whether invention as claimed is obvious – whether person skilled in the art could be reasonably expected to have ascertained, understood and regarded as relevant certain prior art documents – whether certain sources of information would have been combined by the person skilled in the art  

PATENTS – validity – utility

PATENTS – validity – sufficiency and best method

PATENTS – validity – clarity and definition

PATENTS – validity – fair basis

PATENTS – standing to sue for infringement – whether second applicant an exclusive licensee

Legislation: Act revising the Convention on the Grant of European Patents of 29 November 2000 (entered into force on 13 December 2007)
Convention on the Grant of European Patents, opened for signature 5 October 1973, 1065 UNTS 199 (entered into force 7 October 1977)
Patents Act 1990 (Cth) ss 7, 18, 40, 117
Patents Act 1977 (UK)
Cases cited:

ABBOTT RESPIRATORY/Dosage Regime (G02/08) [2010] EPOR 26
Actavis UK Ltd v Janssen Pharmaceutica NV [2008] FSR 35
Actavis UK Ltd v Merck & Co Inc [2009] 1 WLR 1186
Aktiebolaget Hässle v Alphapharm Pty Limited (2002) 212 CLR 411
Alphapharm Pty Ltd v H Lundbeck A/S (2008) 76 IPR 618
AMERICAN CYANAMID/Melamine Derivatives (T279/93) [1999] EPOR 88
Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 2) (2012)

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2015] FCA 634
Decision Date

CaseChat Overview and Summary

In the Federal Court, Otsuka Pharmaceutical Co., Ltd. sought a declaration of non-infringement of a patent against Generic Health Pty Ltd. The patent related to a carbostyril compound, specifically aripiprazole, and its use in treating disorders of the central nervous system, including cognitive impairment in schizophrenia. The case involved a complex discussion of the interpretation and application of Swiss-type patent claims, whether these should be considered methods or processes, and the implications for infringement and validity.

The court had to determine several critical legal issues, including the interpretation of Swiss-type claims, the constitution of the person skilled in the art, and the applicability of the Saccharin doctrine to Swiss-type claims. It also needed to assess whether the patent met the requirements of novelty, inventive step, utility, and sufficiency, as well as whether the person skilled in the art could reasonably be expected to have combined certain prior art documents. Additionally, the court examined whether the second applicant had standing to sue for infringement, given their status as an exclusive licensee.

The court found that the patent claims were not properly characterised as Swiss-type claims and were instead method claims. It held that the team of the person skilled in the art should not be differently constituted based on the specific patent question. The court also determined that the Swiss-type claim could not be infringed by exploiting a medicament manufactured outside the patent area, consistent with the Saccharin doctrine. Regarding validity, the court found that the patent met the requirements of novelty, inventive step, utility, and sufficiency. The court concluded that the second applicant had standing to sue for infringement as an exclusive licensee.

The court ordered the parties to bring in draft orders by a specified date, and if they could not agree on costs, to provide written submissions and a draft order for the court’s consideration.

Orders

Orders of the court

1. The parties are to bring in draft orders giving effect to these reasons by 4.00 pm on 13 July 2015.

2. If the parties are unable to agree on the question of costs, they are to provide short written submissions (not exceeding three pages) on that question, together with a draft of the order that is sought.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

The respondent read affidavits made by the following lay witnesses:·Elmo De Alwis (22 February 2012 and 5 March 2012); and·Timothy Cameron Francis (22 February 2012). BACKGROUND The parties provided an agreed primer of the medical and scientific background relevant to this case: Administrative Exhibit 1. The primer was prepared from the affidavit evidence given by the expert witnesses. The following summary is based substantially on the primer. Schizophrenia and its symptoms Schizophrenia is a serious mental disorder affecting 1% of the population worldwide. It generally comes on in early adulthood. Its main features are disturbances in the ability to experience reality, a lack of capacity to engage with others in the outside world, and disturbances in thinking, behaviour and emotional responses. The disorder may run a number of courses, but standard definitions of schizophrenia state that the symptoms must last for at least six months for the diagnosis to be made. In the majority of cases, the condition is chronic. The cause of schizophrenia is not known, but both genetic factors and environmental stressors operating prenatally and in childhood may play a part. The symptoms of schizophrenia can be classified according to separate dimensions. Positive symptoms and negative symptoms are two of those dimensions. The positive symptoms include hallucinations (the perception of a sensory experience in the absence of a source), delusions (fixed false beliefs not shared by others), and disorganised speech. Negative symptoms include blunting of emotional response, apathy, amotivation and poverty of thought. The Positive and Negative Syndrome Scale (PANSS) is an internationally recognised medical scale used for measuring symptom severity in schizophrenia patients. The PANSS Positive Subscale is used for measuring the positive symptom dimensions of schizophrenia. The PANSS Negative Subscale is used for measuring the negative symptom dimensions of schizophrenia. A reference to, for example, a “PANSS-Negative score” is a reference to a score on the PANSS Negative Subscale. There appears to be universal recognition that the range of symptoms associated with schizophrenia can be categorized around positive symptoms and negative symptoms. This certainly seems to have been the case historically. However, since the 1990s, some have classified the symptoms of schizophrenia by reference to two additional dimensions, namely cognitive symptoms and mood symptoms (including, anxiety and depression). Others have continued to treat cognitive impairment as co-related to the negative symptoms of schizophrenia: cognitive impairment tends to occur together with a patient’s negative symptoms. The diagnosis of schizophrenia is made on the basis of the criteria set out in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV). The diagnosis is made by conducting clinical interviews with the patient, with the aim of eliciting the recognised signs and symptoms of the disorder. The diagnosis may also take into consideration information from collateral sources, such as information from the patient’s relatives and friends, police, and other health care professionals. There are no independent diagnostic tests that would confirm a diagnosis of schizophrenia. However, when a patient presents and is first diagnosed with the disorder, the patient is, by the current definition set out in DSM IV, inevitably suffering positive symptoms.Cognitive impairment and schizophrenia

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established